Hologic, Inc. (NASDAQ:HOLX) has seen a mix of fluctuations in the recent time. Its stock went down by 3.4% following the last earnings report, however, Q3 earnings surpassed estimates and led to a rise in margins. This performance attracted new investors like
Hantz Financial Services Inc. The company has also exceeded market returns and acquired
Endomag to boost its
breast cancer solutions. Some financial institutions increased their holdings in Hologic, including
BNP PARIBAS ASSET MANAGEMENT and
Allspring Global Investments Holdings LLC. Their Q2 earnings also beat estimates and they updated their view for 2024. Hologic also recently completed the acquisition of
Endomagnetics Ltd. Despite some days of underperformance, it continues to surpass guidance and raise its full-year outlook. The company's third-quarter earnings surpassed expectations, even though revenue fell short. Hologic announced strong results and a stock buyback which brought some gains. Following a chip shortage, Hologic is eyeing larger M&A deals and has also acquired
Biotheranostics for $230M. The company is also one of the top players in women's health and diagnostics, took the Covid-19 situation in stride and emerged as a winner.
Hologic HOLX News Analytics from Wed, 09 Jan 2013 08:00:00 GMT to Sun, 01 Sep 2024 13:02:49 GMT -
Rating 4
- Innovation 5
- Information 6
- Rumor 3
